Biomarkers of Primary open-angle glaucoma

Rajendra P Maurya
Editor in Chief IJCEO
Assistant Professor & I/c Orbit, Ocular Oncology and Oculoplasty Unit
Department of Ophthalmology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, (UP), INDIA
E-mail: editorijceo@gmail.com, mauryarp_bhu@yahoo.com

Dear Friends
Season’s Greetings!!

It is my humble privilege to present the special issue of IJCEO after successful journey of two years. This issue of IJCEO has several interesting articles on vision threatening morbidity, Glaucoma particularly on diagnosis and awareness of primary glaucoma.

Primary open angle glaucoma (POAG) is a chronic, progressive, multifactorial neuro-degenerative disorder characterized by loss of retinal ganglion cells and their axon leading to optic nerve cupping and visual field defect. It is the second most common cause of blindness worldwide. Approximately 45 million people have open angle glaucoma and morbidity is expected to be 59 million by 2020.

POAG has no known cause but major ocular risk factors are increased intraocular pressure and aging. Study of biomarkers is necessary in order to further understand the etiological factors in POAG. Biomarkers are molecules available in body fluids and tissues, are indicators of normal biological or pathogenic processes and to monitor the pharmacological response to therapeutic intervention. Biomarkers could be crucial tools for early diagnosis and prognosis of POAG and important tool to identify the individual at risk. Several non-genetic biological markers have been identified which have an association with POAG but still need validation. All known biomarkers of POAG have been isolated in the aqueous humor (AH), trabecular meshwork (TM), optic nerve and blood of the patient.

The basic pathology in POAG is increased resistance to aqueous humor outflow. The extracellular component (ECM) in the TM is essential for normal AH outflow. A depletion in hyaluronic acid and an accumulation of chondroitin sulfates and undigestible glycosaminoglycan have been associated with POAG. sCD44 in AH could be a potential biomarker for POAG. sCD44 is a trans-membrane glycoprotein acting as receptor for hyaluronic acid and participates in its uptake and degradation. POAG is associated with high sCD44 in AH and low level of hyaluronic acid in the TM & Juxta canalicular connective tissues, ECM is constantly modified by surrounding matrix metalloproteinas (MMPs), which initiates turnover of ECM, which in turn is essential for maintenance of the aqueous outflow homeostasis. Endogenous activity of MMP3 & MMP9 in TM may be an important marker.

Expression of fibronectin, laminin and thrombospondin-1 has been shown to be increased in the TM of POAG. The ECM is also modulated by cytokines. The most widely studied cytokine is TGF β. Proteomics study of TM tissues of POAG patient showed increased level of ANGPTL7 which could be involved in pathogenesis of POAG. Elevated level of TGF β2 in AH of glaucoma can lead to increased ANGPTL7.

Several studies show reduced activity of 3α hydroxysteroid dehydrogenase(3α HSD) in peripheral blood lymphocyte from POAG, indicating that 3α HSD may serve as marker of POAG. Those at risk. AP4A (diadenosine tetraphosphate is protective (via anti-apoptotic method) agent. Study showed Oxidative stress increases the concentration of AP4A in AH of POAG patients mainly due to oxidative stress. BDNF (Brain-derived neurotrophic factors) is polypeptide growth factor, is vital component for building up and preserving neurons. It is useful biomarker of early detection of POAG. Significantly lower level of BDNF has been found in tears of normotensive glaucoma patient. There are several biomarkers associated with POAG. The exact role of each biomarker and its direct link to POAG remains to be established.

References